Travere Therapeutics (NASDAQ:TVTX) reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney ...
Q3 earnings swing to loss as revenue rises Travere Therapeutics (TVTX) just delivered third quarter 2026 numbers that pulled investor attention to both sides of the income statement. Revenue reached ...
Investor's Business Daily on MSN
Travere crashed into its 200-day line and then reversed higher; here's why
Shares of Travere Therapeutics took a hit Tuesday, but closed in the green, after fewer than expected patients started taking ...
Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing evidence that FILSPARI® (sparsentan) may modify the underlying disease ...
Travere Therapeutics (Nasdaq: TVTX) will report third quarter 2026 financial results on November 2, 2026, after U.S. financial markets close. Rhea-AI Sentiment reads the wording of the document, how ...
Revenue went the other way. It reached $224.56 million, beating the $192.52 million consensus by 16.6% and growing 36.2% year over year. FILSPARI net sales crossed $200 million for the first time, ...
Travere Therapeutics stock falls 2.2% to $49.26 today after the latest financial results and leadership update.
SAN DIEGO (AP) — SAN DIEGO (AP) — Travere Therapeutics, Inc. (TVTX) on Monday reported a loss of $52.3 million in its third ...
U.S. net product sales for the third quarter of 2026 were $220.2 million, compared to $113.2 million for the same period in ...
Travere Therapeutics (NASDAQ: TVTX) is attempting to change the pattern via which rare kidney diseases are treated. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results